Bio-Rad Laboratories (BIO.B) Competitors

Bio-Rad Laboratories (NYSE:BIO) and Bio-Rad Laboratories (NYSE:BIO.B) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations.

Which has more risk and volatility, BIO or BIO.B?

Bio-Rad Laboratories has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.

Do analysts rate BIO or BIO.B?

Bio-Rad Laboratories presently has a consensus price target of $468.00, suggesting a potential upside of 55.79%. Given Bio-Rad Laboratories' higher probable upside, equities analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Does the media prefer BIO or BIO.B?

In the previous week, Bio-Rad Laboratories had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 7 mentions for Bio-Rad Laboratories and 1 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.46 beat Bio-Rad Laboratories' score of 0.30 indicating that Bio-Rad Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bio-Rad Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher earnings and valuation, BIO or BIO.B?

Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.67B	3.21	-$637.32M	-$21.49	-13.98
Bio-Rad Laboratories	$2.67B	3.61	-$637.32M	-$21.49	-15.75

Do insiders and institutionals hold more shares of BIO or BIO.B?

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are owned by institutional investors. 17.5% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is BIO or BIO.B more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	-23.86%	3.90%	2.77%
Bio-Rad Laboratories	-23.86%	3.90%	2.77%

Does the MarketBeat Community favor BIO or BIO.B?

Bio-Rad Laboratories received 235 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. Likewise, 64.86% of users gave Bio-Rad Laboratories an outperform vote while only 57.60% of users gave Bio-Rad Laboratories an outperform vote.

Company	Underperform	Outperform
Bio-Rad Laboratories	Outperform Votes 360 64.86%	Underperform Votes 195 35.14%
Bio-Rad Laboratories	Outperform Votes 125 57.60%	Underperform Votes 92 42.40%

Summary

Bio-Rad Laboratories beats Bio-Rad Laboratories on 9 of the 11 factors compared between the two stocks.